financetom
Business
financetom
/
Business
/
BRIEF-Casi Pharmaceuticals Announces Plan To Submit Ind Application For Cid-103, An Anti-Cd 38 Antibody In Antibody-Mediated Rejection, And Receipt Of A Non-Binding Proposal To Acquire Entire China Bu
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Casi Pharmaceuticals Announces Plan To Submit Ind Application For Cid-103, An Anti-Cd 38 Antibody In Antibody-Mediated Rejection, And Receipt Of A Non-Binding Proposal To Acquire Entire China Bu
Jun 26, 2024 1:51 PM

CASI Pharmaceuticals Inc ( CASI ):

* CASI PHARMACEUTICALS ANNOUNCES PLAN TO SUBMIT IND

APPLICATION

FOR CID-103, AN ANTI-CD 38 ANTIBODY IN ANTIBODY-MEDIATED

REJECTION, AND RECEIPT OF A NON-BINDING PROPOSAL TO ACQUIRE

ENTIRE CHINA BUSINESS OF THE COMPANY

* CASI PHARMACEUTICALS INC ( CASI ) - TO SUBMIT IND APPLICATION FOR

CID-103

BY END OF 2024

* CASI PHARMACEUTICALS INC ( CASI ) - BOARD GOT A PRELIMINARY

NON-BINDING

PROPOSAL LETTER DATED JUNE 21, FROM WEI-WU HE, CHAIRMAN OF BOARD

AND CEO OF COMPANY

* CASI PHARMACEUTICALS INC ( CASI ) - PROPOSED DEAL FOR PURCHASE

PRICE OF

$40.0 MILLION, WHICH SHALL INCLUDE ASSUMPTION OF UP TO $20.0

MILLION OF INDEBTEDNESS OF COMPANY

Source text for Eikon:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved